CINNARON

This brand name is authorized in Cyprus, Estonia, Singapore.

Active ingredients

The drug CINNARON contains one active pharmaceutical ingredient (API):

1	Cinnarizine UNII 3DI2E1X18L - CINNARIZINE
	Cinnarizine has been shown to be a non-competitive antagonist of the smooth muscle contractions caused by various vasoactive agents including histamine. Cinnarizine also acts on vascular smooth muscle by selectively inhibiting the calcium influx into depolarised cells, thereby reducing the availability of free Ca2+ ions for the induction and maintenance of contraction.
	Read more about Cinnarizine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CINNARON Tablet	MPI, EU: SmPC	Υπουργείο Υγείας (CY)
CINNARON Hard capsule	MPI, EU: SmPC	Υπουργείο Υγείας (CY)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N07CA02	Cinnarizine	N Nervous system → N07 Other nervous system drugs → N07C Antivertigo preparations → N07CA Antivertigo preparations
Discover more medicines within N07CA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1013353, 1085172
SG	Health Sciences Authority	02924P